Clinical trials: Pheochromocytomas
Adrenal Pheochromocytoma, Hemodynamic
Study of Alpha-blockers Alone During Preoperative Preparation in Patients With Pheochromocytoma
Study of the relationship between hemodynamic stability and preoperative intravenous rehydration in patients with pheochromocytoma
- Trial name
- NCT05803330
- Testing
- Abandonment of intravenous volume expansion during preoperative preparation in patients with pheochromocytoma
- Volunteers
- 95 people
- Sponsor
- Kunwu Yan,MM
Neuroblastoma, Pheochromocytoma
Expanded Access Protocol Using 131I-MIBG
Protocol JDI2007-01 is an Expanded Access Protocol with therapeutic 131I-MIBG for patients with neuroblastoma or pheochromocytoma / paraganglioma, who otherwise do not qualify for available treatments, or where approved treatment…
- Conditions
- Neuroblastoma, Pheochromocytoma, Paraganglioma
- Trial name
- NCT01590680
- Testing
- I-131 MIBG
- Where
- 19 sites in United States
- Sponsor
- Jubilant DraxImage Inc.
Pheochromocytoma
Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma
There is currently no standard first-line treatment for stage PPGL, and the 5-year survival rate of patients with advanced pheochromocytoma/paraganglioma (PPGL) is low, ranging from 30% to 60%.
- Trial name
- NCT06429397
- Testing
- Anlotinib and Benmelstobart
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sun Yat-sen University
Pheochromocytoma Malignant
Abdominal Circumference as a Predictor of Operative Time in Retroperitoneal Adrenalectomy for Pheochromocytoma
This retrospective observational study examines whether abdominal circumference is associated with operative time in patients undergoing retroperitoneal adrenalectomy for pheochromocytoma.
- Trial name
- NCT07339241
- Testing
- Retroperitoneal Adrenalectomy
- Volunteers
- 159 people
- Sponsor
- Asan Medical Center
Pheochromocytoma
131MIBG to Treat Malignant Pheochromocytoma
This study will evaluate the effectiveness of 131MIBG in treating malignant pheochromocytoma and whether sensitization medications improve the response to treatment.
- Trial name
- NCT00028106
- Testing
- [131]I-MIBG, 6-[18F]Fluorodopamine, [123]I-MIBG
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Pheochromocytoma, Adrenal Incidentaloma
Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue
To investigate the effect of catecholamine excess on brown fat. To evaluate the effect of brown fat on energy expenditure and lipid and glucose metabolism
- Trial name
- NCT01949714
- Testing
- Removal of adrenal tumor
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Advanced or Metastatic Paraganglioma/ Pheochromocytoma
A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial
This is an open-label phase II study of an investigational drug, anlotinib in participants with advanced malignant paraganglioma or pheochromocytoma.
- Trial name
- EASOAIPPGL (NCT05133349)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pheochromocytoma, Collaboration
Surgeon-Anesthesiologist Collaboration
Collaboration between the surgeon and the anesthesiologist is key for delivering a safe pheochromocytoma surgery. This study aims to establish the collective performance of surgeon-anesthesiologist team by quantifying the…
- Trial name
- CCAP (NCT03158870)
- Testing
- Surgery complications
- Where
- France
- Volunteers
- 1,122 people
- Sponsor
- Hospices Civils de Lyon
Pheochromocytoma
Dexmedetomidine Infusion During Laparoscopic Adrenalectomy
The investigators planned this study to investigate the effects of dexmedetomidine administration on intraoperative hemodynamic stability in patients with pheochromocytoma.
- Trial name
- NCT06037135
- Testing
- dexmedetomidine, 0.9% normal saline
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Pheochromocytoma, Paraganglioma
Zanzalintinib in Unresectable and Progressive MPGGs
This study is to examine the effects of oral daily zanzalintinib in participants with unresectable, progressive metastatic pheochromocytoma or paraganglioma.
- Trial name
- NCT07714551
- Testing
- Zanzalintinib
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Pheochromocytoma and Paraganglioma (PPGL)
Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL)
It is preliminarily clarified that belzutifan exerts an inhibitory effect on catecholamine synthesis in pheochromocytoma and paraganglioma (PPGL), and its safety is simultaneously confirmed, thereby providing preliminary…
- Trial name
- NCT07907341
- Testing
- Belzutifan
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Longfei Liu，MD
Advanced Metastatic Paraganglioma, Advanced Metastatic Pheochromocytoma
Dovitinib in Neuroendocrine Tumors
This study is being conducted to evaluate whether the investigational drug Dovitinib, can shrink or slow the growth of cancer in patients with certain types of neuroendocrine tumors.
- Conditions
- Advanced Metastatic Paraganglioma, Advanced Metastatic Pheochromocytoma, Recurrent Paraganglioma, Recurrent Pheochromocytoma
- Trial name
- NCT01635907
- Testing
- Dovitinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Carcinoma, Renal Cell
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
This was a first in human study of DFF332, a small molecule that targets a protein called HIF2α. By acting on HIF2α, DFF332 may be able to stop the growth of certain types of cancer.
- Trial name
- NCT04895748
- Testing
- DFF332, RAD001, PDR001
- Where
- 11 sites in United States, Czechia and 5 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Paraganglioma, Pheochromocytoma
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
The objectives of this study are: To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma.
- Trial name
- LAMPARA (NCT03946527)
- Testing
- Lanreotide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Antonio Fojo
Neuroendocrine Tumors, Insulinoma
DOTATOC PET/CT for Imaging NET Patients
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called…
- Conditions
- Neuroendocrine Tumors, Insulinoma, Gastrinoma, Glucagonoma
- Trial name
- NCT03583528
- Testing
- 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- British Columbia Cancer Agency
Pheochromocytoma, Neuroblastoma
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.
- Conditions
- Pheochromocytoma, Neuroblastoma, Paraganglioma, Medullary Thyroid Carcinoma
- Trial name
- NCT01373736
- Testing
- 123I-meta-iodobenzylguanidine
- Where
- Canada
- Sponsor
- Vancouver Coastal Health
Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors…
- Conditions
- Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04119024
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Anusha Kalbasi
Pheochromocytoma
the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma
Pheochromocytoma (pheo) is a catecholamine secreting tumor arising from chromaffin cells of the adrenal medulla in 90% of cases \& in 10% is extra-adrenal arising from the sympathetic chain.
- Trial name
- NCT04320589
- Testing
- Dexmedetomidine, General anesthetic
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute, Egypt
Acute Leukemia, Adenomatous Polyposis
Familial Investigations of Childhood Cancer Predisposition
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll.
- Conditions
- Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML
- Trial name
- SJFAMILY (NCT03050268)
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- St. Jude Children's Research Hospital